Bank of America downgraded shares of Humana (NYSE:HUM – Free Report) from a neutral rating to an underperform rating in a research note released on Wednesday, Marketbeat.com reports. They currently have $247.00 price target on the insurance provider’s stock, down from their previous price target of $376.00. A number of other equities research analysts have […]

Humana (NYSE:HUM – Free Report) had its target price trimmed by Oppenheimer from $400.00 to $280.00 in a research report report published on Thursday morning, Benzinga reports. The brokerage currently has an outperform rating on the insurance provider’s stock. Several other brokerages also recently weighed in on HUM. Leerink Partnrs downgraded shares of Humana from […]

Leerink Partners cut shares of Humana (NYSE:HUM – Free Report) from an outperform rating to a market perform rating in a research note released on Wednesday morning, Marketbeat reports. The brokerage currently has $250.00 target price on the insurance provider’s stock, down from their previous target price of $400.00. Other equities analysts have also issued […]

Piper Sandler lowered shares of Humana (NYSE:HUM – Free Report) from an overweight rating to a neutral rating in a research report sent to investors on Thursday morning, MarketBeat.com reports. They currently have $274.00 target price on the insurance provider’s stock, down from their prior target price of $392.00. A number of other brokerages also […]

Deutsche Bank Aktiengesellschaft upgraded shares of RTX (NYSE:RTX – Free Report) from a sell rating to a hold rating in a research note issued to investors on Thursday, Marketbeat Ratings reports. They currently have $129.00 price objective on the stock, up from their prior price objective of $109.00. Other research analysts have also recently issued […]

Bank of America downgraded shares of Charles River Laboratories International (NYSE:CRL – Free Report) from a buy rating to a neutral rating in a report issued on Wednesday, MarketBeat.com reports. The firm currently has $215.00 price target on the medical research company’s stock, down from their prior price target of $250.00. Other equities analysts have […]

Guidewire Software, Inc. (NYSE:GWRE – Get Free Report) hit a new 52-week high during trading on Friday after Oppenheimer raised their price target on the stock from $185.00 to $200.00. Oppenheimer currently has an outperform rating on the stock. Guidewire Software traded as high as $184.33 and last traded at $184.05, with a volume of […]

Bank of America cut shares of Charles River Laboratories International (NYSE:CRL – Free Report) from a buy rating to a neutral rating in a research note published on Wednesday morning, Marketbeat reports. The firm currently has $215.00 price target on the medical research company’s stock, down from their previous price target of $250.00. A number […]

StockNews.com downgraded shares of LPL Financial (NASDAQ:LPLA – Free Report) from a hold rating to a sell rating in a research report released on Tuesday morning. Other equities research analysts have also issued reports about the company. The Goldman Sachs Group cut their target price on LPL Financial from $289.00 to $271.00 and set a […]

Exact Sciences (NASDAQ:EXAS – Free Report) had its price objective increased by Evercore ISI from $72.00 to $80.00 in a report released on Tuesday morning, Benzinga reports. They currently have an outperform rating on the medical research company’s stock. A number of other analysts have also weighed in on the company. Scotiabank started coverage on […]

Hologic (NASDAQ:HOLX – Free Report) had its price objective lifted by Evercore ISI from $78.00 to $82.00 in a research report released on Tuesday morning, Benzinga reports. The firm currently has an in-line rating on the medical equipment provider’s stock. HOLX has been the subject of a number of other research reports. Citigroup cut Hologic […]

StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note published on Wednesday. The firm issued a hold rating on the stock. Several other equities research analysts have also recently issued reports on the company. HC Wainwright decreased their price objective on Oncternal Therapeutics from $19.00 to $18.00 and […]

Stephens downgraded shares of Humana (NYSE:HUM – Free Report) from an overweight rating to an equal weight rating in a research report released on Wednesday morning, Marketbeat reports. The firm currently has $250.00 price objective on the insurance provider’s stock, down from their previous price objective of $400.00. HUM has been the subject of several […]

Bank of America cut shares of Humana (NYSE:HUM – Free Report) from a neutral rating to an underperform rating in a research report sent to investors on Wednesday morning, MarketBeat reports. They currently have $247.00 target price on the insurance provider’s stock, down from their previous target price of $376.00. Several other equities analysts have […]

Lifesci Capital upgraded shares of Liquidia (NASDAQ:LQDA – Free Report) to a strong-buy rating in a research note published on Wednesday, Zacks.com reports. Several other equities analysts have also recently issued reports on the stock. Needham & Company LLC restated a buy rating and issued a $25.00 price target on shares of Liquidia in a […]

Oppenheimer started coverage on shares of Shift4 Payments (NYSE:FOUR – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $109.00 price objective on the stock. Other equities analysts also recently issued reports about the stock. Wells Fargo & Company increased their […]